Brain Scientific Sees Increased First-Quarter Sales Momentum and Revenue Growth


A significant order from a high-tech robotics company highlights growing interest in Piezo Motion’s new series of piezomotors. Additional orders for the Company’s new ferrous-free (non-magnetic) high torque motor underscores its suitability in medical MRI robotics applications.

LAKEWOOD RANCH, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Piezo Motion, a Florida-based Brain Scientific (OTCQB:BRSFD) technology company, announces today increased demand for its new range of novel miniature rotary piezomotors (the RAS Series). The highly precise yet very affordable RAS motor is finding use in a growing range of applications including photonics, medical devices and miniature pumps. 

“We just received our largest order to date for our new miniature motor from a hi-tech company that is working in the photonics space,” said Dr. Mark Broderick, president of Piezo Motion. “It really was just a matter of time before our RAS motor started to get the attention it really deserves.”


Another significant development with Piezo Motion is the growing interest in our new and completely ferrous-free (non-magnetic) high-torque motor. The company received an order from the University of Hawaii and is also collaborating under contract with a US-based designer of medical robotics; both these applications are applying our non-magnetic motor within the field of medical MRI where traditional motors cannot operate.

Along with these large orders, the company reported that a number of entrepreneurs and innovators are doing incredible things with Piezo Motion’s innovative motors. For example, Reuben Brewer, an SRI employee, robotics-class professor at Stanford, and a home robotics lab mad scientist-type said, “I’ve tried out the new motor (RAS), and I love it! It has a very respectable torque, is reliable and a great price compared to alternative and bulkier traditional motors.”

Piezo Motion’s technologies, which are protected by 27 worldwide patents, are applicable to a vast array of diversified markets including:

  • Life science
  • Medical devices
  • Robotics
  • Aerospace
  • Semiconductor
  • Optics
  • Automotive systems 

 “Our piezo motors are filling a unique gap in the market. They are tiny, energy-efficient and precise, yet extremely affordable, finally allowing device manufacturers to use piezoelectric motors for large-scale manufacturing,” said Hassan Kotob, chairman and CEO of Piezo Motion.

About Piezo Motion

Piezo Motion (, a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today’s global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.

About Brain Scientific

Brain Scientific ( is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap™ and NeuroEEG™ are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products or investor relations, please visit

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company’s future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company’s inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company’s raw materials; and the failure to implement the company’s business plans or strategies. Some of these and other factors are identified and described in more detail in the company’s filings with the SEC. The company does not undertake to update these forward-looking statements.


[email protected]

[email protected]

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
310.299.1717 Office
[email protected]

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.